AstraZeneca has temporarily discontinued the coronavirus vaccine trial. A person included in the trials unexpectedly fell ill. Scientists are still trying to find the roots of it. They are contemplating whether it is a side-effect or something different. This vaccine is one of the leading candidates to reach the market. It is being developed along with some researchers at Oxford University.
Managing crisis control
Several companies have been working continuously to obtain a vaccine to stop the Novel Coronavirus. Everyone is looking to enter the competition, whose end result will benefit all humans. The pandemic has hit every country intensely. Moreover, more than 9 million people have died due to it worldwide. Health officials and President Donald Trump have repeatedly said that it is possible to have a vaccine either by the year-end or in early 2021. As per sources, the Data Safety Monitoring Boards in the U.S. and U.K. are conducting an in-depth review of the company’s vaccine trial, which is the standard procedure after an adverse event occurs.
The Scientists’ Perspective
Additionally, some scientists remain unbothered by this halt. Eric Topol, a cardiologist and clinical-trials expert at the Scripps Research Translational Institute in San Diego, refers to this incident as a common one. He claims that the potential illness will likely be unrelated to the vaccine after all. Paul Offit, a pediatrician and vaccine expert at the Children’s Hospital of Philadelphia, claims that the AstraZeneca shot involves giving large doses of a monkey adenovirus engineered so it can’t replicate. He expresses the importance of this chemical being unrelated to the incident.
The U.S. and other governments have made large investments into the making of this vaccine. The trial will only continue once they get a clearance from the Safety Board. Until then, the investigation shall continue.
The Covid-19 vaccine
Recently, AstraZeneca started recruiting people to start conducting vaccine trials. The company is also testing the vaccine developed by Oxford University on volunteers in Britain. The trials are also being conducted in Brazil and South Africa on smaller scales.
Two other vaccines are in the final stages of the trial. One was developed by Moderna Inc. and the other, by Pfizer and Germany’s BioNTech. However, these two vaccines work differently than the ones currently on trial.